School of Medicine


Showing 1,241-1,260 of 2,394 Results

  • Nathan Lo

    Nathan Lo

    Assistant Professor of Medicine (Infectious Diseases) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsOur research group is interested in studying the transmission of infectious diseases and impact of public health interventions with an ultimate goal of informing public health policy. We study a diverse set of pathogens, both domestically and internationally, including vaccine-preventable infections (including COVID-19) and neglected parasitic diseases (such as schistosomiasis). Our group applies diverse computational methodologies, including tools from fields of epidemiology, mathematical and statistical modeling, simulation, and policy analysis.

    A large emphasis of our work is translating scientific evidence into public health policy. Our track record includes multiple studies that have changed policy in the fields of neglected parasitic diseases and COVID-19. We work closely with policy organizations like the World Health Organization and the California Department of Public Health. Nathan was the lead writer of the World Health Organization guidelines on schistosomiasis (2022) and strongyloidiasis (2024).

    Our current research focuses on the following areas:
    (1) Vaccine-preventable infectious diseases (including COVID-19 and measles) in the United States, with a focus on studying vaccines, transmission dynamics, and re-emergence of vaccine-eliminated diseases
    (2) Public health strategies for control and elimination of globally important neglected infectious diseases, such as helminths infections (schistosomiasis, strongyloidiasis) and typhoid fever

    Our current NIH funded projects include:
    (1) Real-time predictive modeling for public health departments to control infectious diseases (DP2 AI170485, PI: Lo)
    (2) Precision mapping of Schistosoma mansoni risk for targeted public health control and elimination (R01 AI179771, PI: Lo)

    Hiring
    We are seeking to fill multiple research positions at all levels. Candidates interested in working on computational public health research related to infectious diseases with a strong quantitative background are highly encouraged to apply. If you an interested, please submit a cover letter, CV, and names of two references to Nathan.Lo@stanford.edu.

  • Quentin Loisel

    Quentin Loisel

    Postdoctoral Scholar, SCRDP/ Heart Disease Prevention

    BioQuentin Loisel is a postdoctoral researcher at the Meta-Research Innovation Center at Stanford (METRICS), where his work focuses on how artificial intelligence is transforming scientific practice and how researchers can use AI to produce better, more robust, and more equitable science. His broader agenda is to help define a hybrid model of scientific inquiry that deliberately and transparently combines human judgment and artificial intelligence.

    His research sits at the intersection of artificial intelligence, epistemology of science, and research systems. He studies how AI tools reshape knowledge production across the research lifecycle, from problem formulation and data analysis to writing, peer review, and governance, and examines the epistemic, methodological, and institutional consequences of human–AI collaboration in science. His work aims to move beyond risk-focused or purely technical perspectives by developing evidence-based, researcher-centric models for integrating AI into everyday scientific practice.

    Before joining Stanford, he completed a Marie Skłodowska-Curie PhD on digital technologies for co-creation, combining cognitive science, collective intelligence, and participatory research. He has co-funded and is coordinating the Artificial Intelligence working group of the Marie Curie Alumni Association (MCAA), which is a researcher-driven community of practice on AI in research. He also advises a social company, called Health Cascade, on how to integrate AI in teams to solve complex societal problems.

  • Karl Lorenz

    Karl Lorenz

    Professor of Medicine (Primary Care and Population Health)

    BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.

  • Kate Lorig

    Kate Lorig

    Professor (Research) of Medicine (Immunology and Rheumatology), Emerita

    Current Research and Scholarly InterestsCommunity based psycoeducational intervention studies of disease self management for people with chronic diseases. arthritis, lung diseases, heart disease AIDs, low back pain and diabetes. Programs and studies in Spanish and English. Interventions are in small groups, mailed or on the Internet.

  • Anson Lowe

    Anson Lowe

    Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus

    Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.

  • Henry J. Lowe, MD

    Henry J. Lowe, MD

    Associate Professor of Medicine (General Medical Disciplines) at the Stanford University Medical Center, Emeritus

    Current Research and Scholarly InterestsMy research in the field of biomedical informatics over the past 30 years has focused on the development of novel uses of information technology and computer science to improve human health. My current interests include the Electronic Health Record (EHR), biomedical knowledge representation, Internet applications in healthcare, clinical data warehouses, clinical data and text mining, academic social networking and the use of information technology to support clinical and translational research.

  • Robert Lowsky

    Robert Lowsky

    Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.

  • Janice Lu

    Janice Lu

    Clinical Professor, Medicine - Oncology

    BioDr. Janice Lu is Clinical Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine. She specializes in the treatment of breast cancer, with expertise in hormone receptor–positive and HER2-positive disease, antibody-drug conjugates, and immunotherapy. Dr. Lu has led and contributed to multiple clinical trials, including playing a key role in the EMERALD trial, which resulted in FDA approval of the first oral SERD for ESR1-mutated ER+/HER2- metastatic breast cancer. Her translational research focuses on liquid biopsy, epigenetics, AI and multiomics approaches to treatment resistance. She has chaired national sessions on precision oncology and holds leadership roles with NRG Oncology and ASCO, including Vice-Chair of the NRG Immunotherapy Subcommittee and Track Leader for ASCO’s Developmental Therapeutics and Targeted Therapy Education Program. She has also served on committees for the National Comprehensive Cancer Network (NCCN) and the Southwest Oncology Group (SWOG).

    Dr. Lu completed her Hematology and Oncology fellowship at New York University School of Medicine and earned a PhD in epigenetics under the mentorship of late Dr. David Allis, a pioneer in the field and 2018 Lasker Laureate. Prior to joining Stanford, she was Director of Breast Medical Oncology and led the Circulating Tumor Cell (CTC) Core Lab at Northwestern University Feinberg School of Medicine, before returning to the Bay Area to be with her family and to further expand research and patient-centered care.